XOMA Announces New U.S. Government Biodefense Subcontract for Development of Therapeutic Antibodies to Treat SARS
BERKELEY, Calif., July 30, 2009 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA - News) today announced that it has been awarded a new $1.7 million subcontract by SRI International to produce novel antibody drugs against the virus that causes severe acute respiratory syndrome (SARS), a highly contagious infectious disease that often progresses to pneumonia and may be fatal. SARS infections resulted in a near-pandemic between late 2002 and mid-2003, when more than 8,000 cases and nearly 800 deaths were reported worldwide
